Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching

Table 1 Patient characteristics prior to second-line treatment (entire cohort)

Characteristics at baseline	n = 86
Age–median (Q1Q3), yr	68.0 (60-74)
Gender, n (%)
Male	77 (90)
Female	9 (10)
Etiology of HCC, n (%)
Alcohol use	30 (35)
Virus/Virus + Alcohol	26 (30)/8 (9)
Non-alcoholic steatohepatitis	13 (15)
Other	9 (10)
ECOG performance status, n (%)
0	33 (38)
1	34 (40)
2	19 (22)
Esophageal varices1, n (%)	36 (45)
Macrovascular invasion, n (%)	41 (48)
Extrahepatic disease, n (%)	37 (43)
Child-Pugh class, n (%)
A	65 (76)
B2	21 (24)
BCLC stage, n (%)
B	15 (17)
C	71 (83)
AFP, ng/mL, n (%)
< 400	45 (52)
≥ 400	41 (48)
HCC morphology3, n (%)
Diffuse	15 (18)
Mass forming	24 (29)
Multinodular	44 (53)
Maximal tumor diameter, mm–median (Q1Q3)	69 (40-100)
Hemoglobin, g/dL–median (Q1Q3)	13 (12-14)
Platelet’s count (× 100/L)–median (Q1Q3)	153 (95-213)
Neutrophil count/L–median (Q1Q3)	3675 (2700-4600)
Lymphocyte count/L–median (Q1Q3)	1118 (810-1650)
Neutrophil-to-lymphocyte ratio, n (%)
≤ 3	40 (47)
> 3	46 (53)
CRP, mg/L–median (Q1Q3)	22 (8-51)
AST, IU/L–median (Q1Q3)	62 (46-117)
ALT, IU/L–median (Q1Q3)	40 (28-64)
GGT, IU/L–median (Q1Q3)	187 (112-360)
ALP, IU/L–median (Q1Q3)	166 (128-267)
Total bilirubin, μmol/L–median (Q1Q3)	17 (12-27)
Albumin, g/L–median (Q1Q3)	35 (29-39)
Creatinine, μmol/L–median (Q1Q3)	70 (57-85)
Prothrombin time, %–median (Q1Q3)	79 (68-93)
Duration of prior Sorafenib treatment, months–median (Q1Q3)	3.5 (2.7-9.2)

¹Esophageal varices, missing data n = 6.

²Child–Pugh grade B: Child–Pugh (CP)-B7 n = 14, CP-B8 n = 4, CP-B9 n = 3.

³Hepatocellular carcinoma morphology, patients with metastatic recurrence and without intrahepatic tumor, n = 3.

HCC: Hepatocellular carcinoma; NASH: Non-alcoholic steatohepatitis; PS: Performance status; BCLC: Barcelona clinic liver cancer; AFP: Alfa-fetoprotein; CRP: C-reactive protein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-glutamyl transpeptidase; ALP: Alkaline phosphatase.